On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...

Former government health officials fear the Trump administration is moving to slow-walk vaccine approvals, including by ...

Novavax faces uncertainty as FDA requests a new clinical trial for its COVID-19 vaccine, the last protein-based option in the ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

HHS Announces Plans to Pay Moderna $176 Million for mRNA Flu Vaccine By Stephanie Brown HealthDay Reporter FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and ...

Moderna's respiratory vaccine sales are not encouraging ... The thing with analyzing a stock like Moderna, Inc. (NASDAQ:MRNA) is that it is more about subjective prospects evaluation than actual ...

NasdaqGS:MRNA Earnings Per Share ... impact earnings forecasts. Moderna's revenue and earnings projections remain pressured by uncertainties in vaccine demand and regulatory challenges.

The surprise delay is casting new uncertainty on the fate of another vaccine awaiting FDA action: Moderna’s next-generation Covid-19 shot, called mRNA-1283, which is set for a decision by May 31.